<DOC>
	<DOCNO>NCT00191763</DOCNO>
	<brief_summary>Based available data , concept neo-adjuvant chemotherapy seem promising patient resectable non-small cell lung cancer . The exploration new drug regimen warrant . Therefore aim study evaluate clinical response rate neo-adjuvant chemotherapy gemcitabine cisplatin patient operable non-small cell lung cancer stage IB , IIA-B , IIIA .</brief_summary>
	<brief_title>Neo-Adjuvant Gemcitabine Cisplatin Treating Patients With Early Stage Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>define histologic cytologic diagnosis non small cell lung cancer . determine presence clinical Stage IB , IIAB IIIA disease accordance revision Mountain CF American Joint Committee Cancer . define performance status 01 ECOG scale prior tumor therapy suitable curative resection treatment within last 30 day investigational drug . get concurrent administration tumor therapy pregnant poorly control diabetes mellitus serious concomitant disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>